These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30134297)

  • 1. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.
    Momper JD; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Badell ML; Acosta EP; Purswani M; Smith E; Chakhtoura N; Park K; Burchett S; Shapiro DE; Mirochnick M;
    AIDS; 2018 Nov; 32(17):2507-2516. PubMed ID: 30134297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
    Momper JD; Wang J; Stek A; Shapiro DE; Powis KM; Paul ME; Badell ML; Browning R; Chakhtoura N; Denson K; Rungruengthanakit K; George K; Capparelli EV; Mirochnick M; Best BM;
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):303-309. PubMed ID: 34732682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.
    Momper JD; Wang J; Stek A; Shapiro DE; Scott GB; Paul ME; Febo IL; Burchett S; Smith E; Chakhtoura N; Denson K; Rungruengthanakit K; George K; Yang DZ; Capparelli EV; Mirochnick M; Best BM;
    AIDS; 2021 Jul; 35(8):1191-1199. PubMed ID: 34076612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
    Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
    AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
    Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
    Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint.
    Boyd SD; Sampson MR; Viswanathan P; Struble KA; Arya V; Sherwat AI
    AIDS; 2019 May; 33(6):1089-1093. PubMed ID: 30946163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
    Crauwels HM; Osiyemi O; Zorrilla C; Bicer C; Brown K
    HIV Med; 2019 May; 20(5):337-343. PubMed ID: 30873741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
    Brooks KM; Momper JD; Pinilla M; Stek AM; Barr E; Weinberg A; Deville JG; Febo IL; Cielo M; George K; Denson K; Rungruengthanakit K; Shapiro DE; Smith E; Chakhtoura N; Rooney JF; Haubrich R; Espina R; Capparelli EV; Mirochnick M; Best BM;
    AIDS; 2021 Mar; 35(3):407-417. PubMed ID: 33252495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
    Shiomi M; Matsuki S; Ikeda A; Ishikawa T; Nishino N; Kimura M; Kumagai Y; Irie S
    Clin Pharmacol Drug Dev; 2015; 4(3):218-25. PubMed ID: 27140802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
    Barceló C; Gaspar F; Aouri M; Panchaud A; Rotger M; Guidi M; Cavassini M; Buclin T; Decosterd LA; Csajka C;
    J Antimicrob Chemother; 2016 Jul; 71(7):1933-42. PubMed ID: 27029846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
    Tran AH; Best BM; Stek A; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; George K; Cressey TR; Chakhtoura N; Smith E; Shapiro DE; Mirochnick M;
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):289-96. PubMed ID: 26918544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of tenofovir during pregnancy and postpartum.
    Best BM; Burchett S; Li H; Stek A; Hu C; Wang J; Hawkins E; Byroads M; Watts DH; Smith E; Fletcher CV; Capparelli EV; Mirochnick M;
    HIV Med; 2015 Sep; 16(8):502-11. PubMed ID: 25959631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum: a case report.
    Marzolini C; Decosterd L; Winterfeld U; Tissot F; Francini K; Buclin T; Livio F
    Br J Clin Pharmacol; 2017 Dec; 83(12):2835-2838. PubMed ID: 28512794
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s.
    Brooks KM; Pinilla M; Stek AM; Shapiro DE; Barr E; Febo IL; Paul ME; Deville JG; George K; Knowles K; Rungruengthanakit K; Browning R; Chakhtoura N; Capparelli EV; Mirochnick M; Best BM;
    J Acquir Immune Defic Syndr; 2022 Jul; 90(3):343-350. PubMed ID: 35195573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
    Gutierrez-Valencia A; Benmarzouk-Hidalgo OJ; Llaves S; Fernandez-Magdaleno T; Espinosa N; Viciana P; Lopez-Cortes LF
    J Antimicrob Chemother; 2017 Mar; 72(3):816-819. PubMed ID: 27999051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically Significant Lower Elvitegravir Exposure During the Third Trimester of Pregnant Patients Living With Human Immunodeficiency Virus: Data From the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Network.
    Bukkems V; Necsoi C; Tenorio CH; Garcia C; Rockstroh J; Schwarze-Zander C; Lambert JS; Burger D; Konopnicki D; Colbers A
    Clin Infect Dis; 2020 Dec; 71(10):e714-e717. PubMed ID: 32330231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.
    Stek A; Best BM; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; Cressey TR; Mofenson LM; Smith E; Shapiro D; Mirochnick M
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):33-41. PubMed ID: 25950206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
    Imaz A; Niubó J; Kashuba AD; Ferrer E; Sykes C; Rozas N; Acerete L; Vila A; Podzamczer D
    HIV Med; 2017 Mar; 18(3):225-230. PubMed ID: 27477062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.
    Blonk MI; Colbers AP; Hidalgo-Tenorio C; Kabeya K; Weizsäcker K; Haberl AE; Moltó J; Hawkins DA; van der Ende ME; Gingelmaier A; Taylor GP; Ivanovic J; Giaquinto C; Burger DM; ;
    Clin Infect Dis; 2015 Sep; 61(5):809-16. PubMed ID: 25944344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
    Nguyen B; Foisy MM; Hughes CA
    Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.